Susquehanna International Group’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-12,800
| Closed | -$189K | – | 13617 |
|
|
2024
Q1 | $189K | Sell |
12,800
-69,900
| -85% | -$982K | ﹤0.01% | 10653 |
|
|
2023
Q4 | $1.11M | Buy |
82,700
+30,800
| +59% | +$389K | ﹤0.01% | 6748 |
|
|
2023
Q3 | $640K | Buy |
51,900
+6,600
| +15% | +$79.9K | ﹤0.01% | 7656 |
|
|
2023
Q2 | $557K | Buy |
45,300
+27,500
| +154% | +$344K | ﹤0.01% | 8068 |
|
|
2023
Q1 | $219K | Sell |
17,800
-19,100
| -52% | -$224K | ﹤0.01% | 10407 |
|
|
2022
Q4 | $423K | Buy |
36,900
+16,500
| +81% | +$136K | ﹤0.01% | 8285 |
|
|
2022
Q3 | $77K | Buy |
+20,400
| New | +$94.2K | ﹤0.01% | 11922 |
|
|
2022
Q2 | – | Sell |
-16,500
| Closed | -$104K | – | 14628 |
|
|
2022
Q1 | $104K | Sell |
16,500
-14,100
| -46% | -$79.2K | ﹤0.01% | 11885 |
|
|
2021
Q4 | $120K | Sell |
30,600
-7,300
| -19% | -$31.7K | ﹤0.01% | 12005 |
|
|
2021
Q3 | $183K | Buy |
+37,900
| New | +$198K | ﹤0.01% | 11599 |
|
|
2021
Q2 | – | Sell |
-22,300
| Closed | -$140K | – | 13755 |
|
|
2021
Q1 | $140K | Sell |
22,300
-271,500
| -92% | -$1.94M | ﹤0.01% | 11699 |
|
|
2020
Q4 | $2.02M | Buy |
293,800
+268,800
| +1,075% | +$1.33M | ﹤0.01% | 5070 |
|
|
2020
Q3 | $100K | Buy |
+25,000
| New | +$91.8K | ﹤0.01% | 9919 |
|
|
2020
Q1 | – | Sell |
-33,200
| Closed | -$105K | – | 11400 |
|
|
2019
Q4 | $105K | Sell |
33,200
-6,700
| -17% | -$26.8K | ﹤0.01% | 9123 |
|
|
2019
Q3 | $179K | Buy |
39,900
+10,667
| +36% | +$53.3K | ﹤0.01% | 9204 |
|
|
2019
Q2 | $139K | Buy |
29,233
+9,151
| +46% | +$43.4K | ﹤0.01% | 9427 |
|
|
2019
Q1 | $110K | Buy |
+20,082
| New | +$92.3K | ﹤0.01% | 8210 |
|
|
2018
Q4 | – | Sell |
-40,672
| Closed | -$171K | – | 10687 |
|
|
2018
Q3 | $171K | Sell |
40,672
-34,317
| -46% | -$145K | ﹤0.01% | 8337 |
|
|
2018
Q2 | $290K | Buy |
74,989
+6,101
| +9% | +$40.5K | ﹤0.01% | 7911 |
|
|
2018
Q1 | $436K | Buy |
68,888
+47,789
| +226% | +$395K | ﹤0.01% | 6913 |
|
|
2017
Q4 | $170K | Sell |
21,099
-25,038
| -54% | -$233K | ﹤0.01% | 8410 |
|
|
2017
Q3 | $528K | Buy |
46,137
+31,050
| +206% | +$326K | ﹤0.01% | 6421 |
|
|
2017
Q2 | $147K | Sell |
15,087
-2,186
| -13% | -$44.7K | ﹤0.01% | 8506 |
|
|
2017
Q1 | $419K | Buy |
17,273
+4,055
| +31% | +$101K | ﹤0.01% | 6808 |
|
|
2016
Q4 | $424K | Buy |
13,218
+2,783
| +27% | +$119K | ﹤0.01% | 7323 |
|
|
2016
Q3 | $521K | Buy |
+10,435
| New | +$433K | ﹤0.01% | 5983 |
|
|
2016
Q2 | – | Sell |
-5,440
| Closed | -$358K | – | 9852 |
|
|
2016
Q1 | $358K | Buy |
5,440
+3,317
| +156% | +$173K | ﹤0.01% | 6972 |
|
|
2015
Q4 | $132K | Sell |
2,123
-3,419
| -62% | -$241K | ﹤0.01% | 8742 |
|
|
2015
Q3 | $371K | Sell |
5,542
-25,013
| -82% | -$2.04M | ﹤0.01% | 7664 |
|
|
2015
Q2 | $2.97M | Buy |
30,555
+8,973
| +42% | +$854K | ﹤0.01% | 3868 |
|
|
2015
Q1 | $2.02M | Buy |
21,582
+11,465
| +113% | +$976K | ﹤0.01% | 4314 |
|
|
2014
Q4 | $899K | Sell |
10,117
-26,157
| -72% | -$1.91M | ﹤0.01% | 6073 |
|
|
2014
Q3 | $2.51M | Sell |
36,274
-16,460
| -31% | -$880K | ﹤0.01% | 4213 |
|
|
2014
Q2 | $3.02M | Buy |
52,734
+28,293
| +116% | +$1.44M | ﹤0.01% | 3908 |
|
|
2014
Q1 | $969K | Sell |
24,441
-6,876
| -22% | -$294K | ﹤0.01% | 5571 |
|
|
2013
Q4 | $1.32M | Buy |
31,317
+29,309
| +1,460% | +$850K | ﹤0.01% | 4996 |
|
|
2013
Q3 | $60K | Sell |
2,008
-1,347
| -40% | -$47.1K | ﹤0.01% | 8197 |
|
|
2013
Q2 | $178K | Buy |
+3,355
| New | +$147K | ﹤0.01% | 7524 |
|
Other funds holding MACK
RA
JC
Susquehanna International Group's MACK Position: Q2 2024 in Review
Susquehanna International Group sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 77,397 shares — an estimated $1.14M sold.
Susquehanna International Group first reported a position in MACK in Q3 2013 and held it in 34 quarters. The position peaked at $4.36M in Q4 2013. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.
- Susquehanna International Group reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- Susquehanna International Group sold 77,397 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $1.14M.
- Susquehanna International Group first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 34 quarters.
- Susquehanna International Group's Merrimack Pharmaceuticals, Inc. position peaked at $4.36M in Q4 2013.
- 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.
Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.